Connaughton Bernadette sold $167K of HALO
Connaughton Bernadette sold 1,626 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $102.80 ($0.17M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is a director open-market sale of common stock under a pre-arranged 10b5-1 plan; it does not provide new guidance, trial results, or regulatory updates.
Market read
Traders may note the transaction for positioning, but it is unlikely to drive meaningful repricing absent other company-specific news.
What to watch
The filing states the sale was under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Background
The article is an SEC Form 4 insider transaction disclosure for Halozyme Therapeutics, Inc.
Ticker impact
Connaughton Bernadette, a HALO director, sold 1,626 shares at $102.80 on 2026-08-10 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price impact; any reaction is likely muted and short-lived.
Form 4 details a planned sale (10b5-1) and does not include new company-specific operational or financial information.
Market effects
No sector read-through; this is an individual insider transaction without new regulatory, clinical, or product catalysts.
None indicated.
None indicated.
Counterpoint
A director sale can still reflect personal liquidity needs, but traders may briefly overinterpret it as bearish if they ignore the 10b5-1 context.
Key entities
- issuerHALO
Halozyme Therapeutics, Inc., the company whose shares were sold by a director.
- insiderConnaughton Bernadette
Director who sold 1,626 shares at $102.80 on 2026-08-10 under a 10b5-1 plan.
